EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept

Krzysztof Kamiński iD, Katarzyna Socała, Michał Abram, Marcin Jakubiec, Katelyn L Reeb, Rhea Temmermand, Mirosław Zagaja, Maciej Maj, Magdalena Kolasa, Agata Faron-Górecka, Marta Andres-Mach, Aleksandra Szewczyk und 4 weitere

Annals of Neurology · 2025-02 · 97 (2) · 344-357

DOI: 10.1002/ana.27124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 08.11.2024. Verfasst von Krzysztof Kamiński und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland. Hauptthemen laut MEDLINE: Glutamic Acid, Anticonvulsants, Seizures, Epilepsy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Science Centre, Poland, Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Excitotoxicity is a common hallmark of epilepsy and other neurological diseases associated with elevated extracellular glutamate levels. Thus, here, we studied the protective effects of ( R )‐AS‐1 , a positive allosteric modulator (PAM) of glutamate uptake in epilepsy models.

Methods

( R )‐AS‐1 was evaluated in a range of acute and chronic seizure models, while its adverse effect profile was assessed in a panel of standard tests in rodents. The effect of ( R )‐AS‐1 on glutamate uptake was assessed in COS‐7 cells expressing the transporter. WAY 213613, a selective competitive EAAT2 inhibitor, was used to probe the reversal of the enhanced glutamate uptake in the same transporter expression system. Confocal microscopy and Western blotting analyses were used to study a potential influence of ( R )‐AS‐1 on GLT‐1 expression in mice.

Results

( R )‐AS‐1 showed robust protection in a panel of animal models of seizures and epilepsy, including the maximal electroshock‐ and 6 Hz‐induced seizures, corneal kindling, mesial temporal lobe epilepsy, lamotrigine‐resistant amygdala kindling, as well as seizures induced by pilocarpine or Theiler's murine encephalomyelitis virus. Importantly, ( R )‐AS‐1 displayed a favorable adverse effect profile in the rotarod, the minimal motor impairment, and the Irwin tests. ( R )‐AS‐1 enhanced glutamate uptake in vitro and this effect was abolished by WAY 213613, while no influence on GLT‐1 expression in vivo was observed after repeated treatment.

Interpretation

Collectively, our results show that ( R )‐AS‐1 has favorable tolerability and provides robust preclinical efficacy against seizures. Thus, allosteric enhancement of EAAT2 function could offer a novel therapeutic strategy for treatment of epilepsy and potentially other neurological disorders associated with glutamate excitotoxicity. ANN NEUROL 2025;97:344–357

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glutamic AcidAnticonvulsantsSeizuresEpilepsyAnimalsMiceChlorocebus aethiopsMaleCOS CellsDisease Models, AnimalExcitatory Amino Acid Transporter 2RatsProof of Concept StudyMice, Inbred C57BL

Substanzen

Glutamic AcidAnticonvulsantsExcitatory Amino Acid Transporter 2

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland.
  • Department of Animal Physiology and Pharmacology, Institute of Biological Sciences, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland.
  • Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, USA.
  • Department of Experimental Pharmacology, Institute of Rural Health, Lublin, Poland.
  • Department of Biopharmacy, Medical University of Lublin, Lublin, Poland.
  • Department of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland.

ORCID-Profile: Krzysztof Kamiński, Mustafa Q Hameed, Andréia C K Fontana, Alexander Rotenberg

Förderung

  • NINDS NIH HHS
  • National Science Centre, Poland
  • Narodowe Centrum Nauki
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Kamiński, K., Socała, K., Abram, M., Jakubiec, M., Reeb, K. L., Temmermand, R., Zagaja, M., Maj, M., Kolasa, M., Faron-Górecka, A., Andres-Mach, M., Szewczyk, A., Hameed, M. Q., Fontana, A. C. K., Rotenberg, A., & Kamiński, R. M. (2025). Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept. Annals of Neurology, 97(2), 344-357. https://doi.org/10.1002/ana.27124

Vancouver

Kamiński K, Socała K, Abram M, Jakubiec M, Reeb KL, Temmermand R, et al. Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept. Annals of Neurology. 2025;97(2):344-357. doi:10.1002/ana.27124

BibTeX
@article{Kamiski2025,
  author = {Kamiński, Krzysztof and Socała, Katarzyna and Abram, Michał and Jakubiec, Marcin and Reeb, Katelyn L and Temmermand, Rhea and Zagaja, Mirosław and Maj, Maciej and Kolasa, Magdalena and Faron-Górecka, Agata and Andres-Mach, Marta and Szewczyk, Aleksandra and Hameed, Mustafa Q and Fontana, Andréia C K and Rotenberg, Alexander and Kamiński, Rafał M},
  title = {Enhancement of Glutamate Uptake as Novel Antiseizure Approach: Preclinical Proof of Concept},
  journal = {Annals of Neurology},
  year = {2025},
  volume = {97},
  number = {2},
  pages = {344--357},
  doi = {10.1002/ana.27124}
}
Kostenlos starten →